Patient Selection for Plaque Psoriasis Oral Systemic Treatments

This is a video synopsis of a discussion involving April W. Armstrong, MD, MPH, Professor and Chief of Dermatology at UCLA, and Chair Emeritus of the Medical Board of the National Psoriasis Foundation. Dr. Armstrong specializes in psoriasis and atopic dermatitis.

Dr. Armstrong discusses patient selection criteria for oral systemic treatments, noting that patients who prefer oral medications and have moderate-to-severe psoriasis are good candidates. She highlights the efficacy and tolerability of deucravacitinib, particularly for patients with palmoplantar involvement, where oral medications may outperform biologics.

She acknowledges the efficacy of deucravacitinib even in patients who have previously failed biologic therapies, possibly due to its targeting of the IL-23 pathway. Dr. Armstrong suggests considering switching such patients to IL-23 medications, either orally via deucravacitinib or through IL-23 biologics.

Emphasizing the multitude of treatment options available, Dr. Armstrong highlights deucravacitinib as an oral therapy with efficacy similar to first-generation biologics and a consistent safety profile. She notes that patients now have access to oral therapies that offer significant efficacy, comparable to biologics, providing a valuable treatment option for those who prefer oral medications.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.